Baseline characteristics of the patients
| Patient characteristics | Dupilumab (n = 6) |
|---|---|
| Age (y), mean (SD) | 53.1 (7.4) |
| Sex, male; n (%) | 3 (50) |
| GINA steps 1–4, n (%) | 5 (83.3) |
| NSAID-exacerbated respiratory disease (N-ERD), n (%) | 3 (50) |
| Use of systemic steroids in the last year, n (%) | 5 (83.3) |
| Number of polypectomies in the last year, n (%) | |
| 3 or more | 3 (50) |
| 2 | 2 (33.3) |
| 1 | 1 (16.7) |
| Sensitization to aeroallergens, n (%) | 3 (50) |
| 3 years SCIT before treatment with dupilumab | 1 (16.7) |
GINA: Global Initiative for Asthma; NSAID: nonsteroidal anti-inflammatory drug; SCIT: subcutaneous immunotherapy
